Radiation-induced second cancers: the impact of 3D-CRT and IMRT
- PMID: 12694826
- DOI: 10.1016/s0360-3016(03)00073-7
Radiation-induced second cancers: the impact of 3D-CRT and IMRT
Abstract
Information concerning radiation-induced malignancies comes from the A-bomb survivors and from medically exposed individuals, including second cancers in radiation therapy patients. The A-bomb survivors show an excess incidence of carcinomas in tissues such as the gastrointestinal tract, breast, thyroid, and bladder, which is linear with dose up to about 2.5 Sv. There is great uncertainty concerning the dose-response relationship for radiation-induced carcinogenesis at higher doses. Some animal and human data suggest a decrease at higher doses, usually attributed to cell killing; other data suggest a plateau in dose. Radiotherapy patients also show an excess incidence of carcinomas, often in sites remote from the treatment fields; in addition there is an excess incidence of sarcomas in the heavily irradiated in-field tissues. The transition from conventional radiotherapy to three-dimensional conformal radiation therapy (3D-CRT) involves a reduction in the volume of normal tissues receiving a high dose, with an increase in dose to the target volume that includes the tumor and a limited amount of normal tissue. One might expect a decrease in the number of sarcomas induced and also (less certain) a small decrease in the number of carcinomas. All around, a good thing. By contrast, the move from 3D-CRT to intensity-modulated radiation therapy (IMRT) involves more fields, and the dose-volume histograms show that, as a consequence, a larger volume of normal tissue is exposed to lower doses. In addition, the number of monitor units is increased by a factor of 2 to 3, increasing the total body exposure, due to leakage radiation. Both factors will tend to increase the risk of second cancers. Altogether, IMRT is likely to almost double the incidence of second malignancies compared with conventional radiotherapy from about 1% to 1.75% for patients surviving 10 years. The numbers may be larger for longer survival (or for younger patients), but the ratio should remain the same.
Comment in
-
Production and killing of second cancer precursor cells in radiation therapy: in regard to Hall and Wuu (Int J Radiat Oncol Biol Phys 2003;56:83-88).Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):916. doi: 10.1016/j.ijrobp.2003.09.076. Int J Radiat Oncol Biol Phys. 2004. PMID: 15183501 No abstract available.
Similar articles
-
The effect of intensity-modulated radiotherapy on radiation-induced second malignancies.Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1530-6. doi: 10.1016/j.ijrobp.2007.08.046. Epub 2008 Jan 22. Int J Radiat Oncol Biol Phys. 2008. PMID: 18207670
-
Exposure of remote organs and associated cancer risks from tangential and multi-field breast cancer radiotherapy.Strahlenther Onkol. 2019 Jan;195(1):32-42. doi: 10.1007/s00066-018-1384-1. Epub 2018 Oct 22. Strahlenther Onkol. 2019. PMID: 30350118 English.
-
Constituent components of out-of-field scatter dose for 18-MV intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy: a comparison with 6-MV and implications for carcinogenesis.Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):645-53. doi: 10.1016/j.ijrobp.2014.05.052. Epub 2014 Jul 30. Int J Radiat Oncol Biol Phys. 2014. PMID: 25084609
-
Intensity-modulated radiation therapy, protons, and the risk of second cancers.Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7. doi: 10.1016/j.ijrobp.2006.01.027. Int J Radiat Oncol Biol Phys. 2006. PMID: 16618572 Review.
-
Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review.Radiother Oncol. 2009 Apr;91(1):4-15; discussion 1-3. doi: 10.1016/j.radonc.2008.12.016. Epub 2009 Feb 5. Radiother Oncol. 2009. PMID: 19201045 Review.
Cited by
-
Radiation-induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma.Chin J Cancer. 2016 Oct 12;35(1):89. doi: 10.1186/s40880-016-0153-8. Chin J Cancer. 2016. PMID: 27729091 Free PMC article.
-
Dosimetric evaluation of VMAT and helical tomotherapy techniques comparing conventional volumes with clinical target volumes based on new ESTRO ACROP post-mastectomy with immediate implant reconstruction contouring guidelines.Radiat Oncol. 2022 Oct 21;17(1):168. doi: 10.1186/s13014-022-02134-y. Radiat Oncol. 2022. PMID: 36271401 Free PMC article.
-
Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer.Radiat Oncol. 2013 Mar 4;8:47. doi: 10.1186/1748-717X-8-47. Radiat Oncol. 2013. PMID: 23452670 Free PMC article. Clinical Trial.
-
Dosimetric analysis of isocentrically shielded volumetric modulated arc therapy for locally recurrent nasopharyngeal cancer.Sci Rep. 2016 May 13;6:25959. doi: 10.1038/srep25959. Sci Rep. 2016. PMID: 27173670 Free PMC article.
-
The differential role of human macrophage in triggering secondary bystander effects after either gamma-ray or carbon beam irradiation.Cancer Lett. 2015 Jul 10;363(1):92-100. doi: 10.1016/j.canlet.2015.04.013. Epub 2015 Apr 17. Cancer Lett. 2015. PMID: 25896631 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials